Nazeer T, Ro J Y, Amato R J, Park Y W, Ordonez N G, Ayala A G
Department of Pathology, The University of Texas, M.D. Anderson Cancer Center, Houston, TX 77030, USA.
Oncol Rep. 1998 Nov-Dec;5(6):1425-9. doi: 10.3892/or.5.6.1425.
Seminomas account for 50% of testicular germ-cell tumors, and more than 90% of these are classic seminomas. When patients with a histologically pure testicular seminoma show an elevated level of serum á-fetoprotein (AFP), it is generally assumed that an undetected focus of yolk sac tumor (YST) is present and the patient is managed with a treatment regimen for non-seminomatous tumor. We studied 10 cases of histologically pure seminoma with elevated levels of serum AFP in an attempt to identify any distinctive clinical, histopathologic, or immunohistochemical features. The patients ranged in age from 27 to 48 years (mean, 31 years). Eight patients had primary tumors of the testis, and two presented with supraclavicular and ileal tumors. The clinical stage at presentation varied: four tumors were stage I, four were stage II, and two were stage III. Serum levels of AFP were elevated in all patients at ranges of 10.4 to 16 ng/ml (mean, 12.0 ng/ml). In all patients, the primary tumors and metastases when present exhibited classic seminoma histology without other germ-cell components. The tumor cells expressed keratin in seven cases. The pattern of keratin immunoreactivity ranged from focal staining in five cases to moderate staining in two cases. All cases were negative for AFP, and the nine cases in which staining for CD30 (Ki-1) was performed were also negative. All four patients with stage I tumors underwent the conventional therapy for pure seminoma, i.e., orchiectomy and subsequent radiation therapy. Five patients received treatment for non-seminomatous tumors, i.e., chemotherapy after orchiectomy. Extensive work-up failed to detect the primary tumor in one patient, and he was treated for a non-seminomatous tumor, undergoing chemotherapy and irradiation. All patients are alive and well, and none has developed evidence of YST at a mean follow-up of 6 years (range, 6 months to 10 years). However, one patient who presented with an ileal metastasis recently developed a second primary extragonadal mediastinal mixed germ-cell tumor with YST and embryonal carcinoma components and an elevated serum level of AFP (27,000 ng/ml) after a 10-year disease-free follow-up. This study strongly suggests that minor elevations (</= 16 ng/ml) of AFP in patients with an otherwise pure seminoma may not indicate that there is a hidden focus of YST and that such patients should be treated with standard therapy for seminoma. Because this study includes very few patients, further studies are required to better understand the significance of borderline elevations of AFP in cases of histologically pure seminoma.
精原细胞瘤占睾丸生殖细胞肿瘤的50%,其中90%以上为经典型精原细胞瘤。当组织学上为纯睾丸精原细胞瘤的患者血清甲胎蛋白(AFP)水平升高时,通常认为存在未被检测到的卵黄囊瘤(YST)病灶,并按照非精原细胞瘤的治疗方案对患者进行处理。我们研究了10例组织学上为纯精原细胞瘤且血清AFP水平升高的病例,试图确定任何独特的临床、组织病理学或免疫组化特征。患者年龄在27至48岁之间(平均31岁)。8例患者原发肿瘤位于睾丸,2例表现为锁骨上和回肠肿瘤。就诊时的临床分期各不相同:4例为I期,4例为II期,2例为III期。所有患者血清AFP水平均升高,范围为10.4至16 ng/ml(平均12.0 ng/ml)。所有患者的原发肿瘤及转移灶(如有)均表现为经典的精原细胞瘤组织学特征,无其他生殖细胞成分。7例肿瘤细胞表达角蛋白。角蛋白免疫反应模式从5例的局灶性染色到2例的中度染色不等。所有病例AFP均为阴性,9例行CD30(Ki-1)染色的病例也为阴性。4例I期肿瘤患者均接受了纯精原细胞瘤的常规治疗,即睾丸切除术及后续放疗。5例患者接受了非精原细胞瘤的治疗,即睾丸切除术后化疗。1例患者经全面检查未能发现原发肿瘤,接受了非精原细胞瘤的治疗,进行了化疗和放疗。所有患者均存活且情况良好,平均随访6年(范围6个月至10年),均未出现YST证据。然而,1例以回肠转移就诊的患者在无病随访10年后,最近发生了第二原发性性腺外纵隔混合性生殖细胞肿瘤,伴有YST和胚胎癌成分,血清AFP水平升高(27,000 ng/ml)。本研究强烈提示,在其他方面为纯精原细胞瘤的患者中,AFP轻度升高(≤16 ng/ml)可能并不表明存在隐匿的YST病灶此类患者应接受精原细胞瘤的标准治疗。由于本研究纳入的患者很少,需要进一步研究以更好地了解组织学上为纯精原细胞瘤病例中AFP临界升高的意义。